# Genocea Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genocea-biosciences

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.genocea.com
- Total disclosed funding: $73M
- Latest round: Series C (Oct 10, 2012)
- Investors on record: 13

## About

Genocea Biosciences, Inc. is a biotechnology company focused on developing vaccines and immunotherapies for cancer and infectious diseases. The firm employs innovative technologies to harness the immune system.Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, US. The company specializes in immunotherapy, focusing on harnessing the immune system for therapeutic purposes. Over its history, Genocea has raised a total of USD 75.60 mn across multiple funding rounds, with the latest funding being a Private Placement/Follow on in July 2020, where it raised USD 75.60 mn by selling shares at USD 2.25 each. Chip Clark serves as the CEO.Genocea Biosciences delivers innovative products primarily in the fields of cancer and infectious disease immunotherapy. The company's offerings are centered on developing vaccines and harnessing the power of the immune system to create effective treatments tailored to specific patient needs.For the year 2021, Genocea Biosciences reported a total revenue of USD 1.64 mn, with an EBITDA loss of USD 50.54 mn for the same year.Genocea Biosciences aims to leverage its recent funding to expand its pipeline of immunotherapies and vaccines. The company plans to introduce new products targeting various infectious diseases and cancer treatments within the next few years. Additionally, it seeks to explore expansion into international markets, particularly in Europe and Asia, by 2023, utilizing the USD 75.60 mn raised to support these growth initiatives.

## Funding rounds

- Series C, Oct 10, 2012, $15M — Auriga Partners, Polaris Partners, Skyline Ventures, SR One, Johnson & Johnson Innovation, Cycad Group, 5Y Capital, Lux Capital, MP Healthcare Venture Management, Bill & Melinda Gates Foundation, Henry Crown and Company, Morningside
- Series B, Jan 3, 2011, $35M — Auriga Partners, Polaris Partners, Skyline Ventures, SR One, Johnson & Johnson Innovation, Cycad Group, 5Y Capital, Lux Capital, MP Healthcare Venture Management
- Series A, Feb 19, 2009, $23M — Auriga Partners, Polaris Partners, SR One, Alexandria Venture Investments, Cycad Group, 5Y Capital, Lux Capital
- Seed, Jun 1, 2006 — Polaris Partners, 5Y Capital, Lux Capital

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Seed, Series A, Series B, Series C
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Seed, Series A, Series B, Series C
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Seed, Series A, Series B, Series C
- Auriga Partners (https://capitalatlas.ai/funds/auriga-partners) — Series A, Series B, Series C
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A, Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Cycad Group (https://capitalatlas.ai/funds/cycad-group) — Series A, Series B, Series C
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series B, Series C
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B, Series C
- MP Healthcare Venture Management (https://capitalatlas.ai/funds/mp-healthcare-venture-management) — Series B, Series C
- Bill & Melinda Gates Foundation — Series C
- Henry Crown and Company — Series C
- Morningside (https://capitalatlas.ai/funds/morningside) — Series C